National Center for Advancing Translational Sciences - Small Business
Active
- Assistance listing
- 93.TR5
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Grant awards
- Not on record
Program facts
- Also known as
- NCATS - SBIR/STTR
- Treasury account
-
- 75-0875-0-1-552
- More information
Program details come from SAM.gov Assistance Listings. Updated .
About this program
The National Institutes of Health's National Center for Advancing Translational Sciences administers SBIR and STTR grants (CFDA 93.TR5) to help small businesses develop and commercialize translational technologies that accelerate the pathway from research observation to health solutions, with no recent award date visible in available records.
The program funds development, testing, and implementation of diagnostics and novel drugs, devices, or interventions aimed at reducing the typical 14-year, $2 billion development cycle and 95% failure rate that characterize translational research commercialization. NCATS targets small businesses eligible to receive federal SBIR and STTR funding, using both grant and cooperative agreement mechanisms to support technology development with eventual commercial application across the translational research ecosystem.
The source does not provide recent grant award data, award portfolio composition, funding concentration among NIH sub-agencies, typical award magnitudes, or examples of recently funded projects. The source does not identify currently open grant opportunities or recent solicitation activity. The material present focuses on evaluation criteria (scientific merit, technical adequacy, investigator competency, facility adequacy, budget necessity, program relevance, and fund availability), peer review procedures, and administrative requirements including 3-year record retention and standard HHS audit access rights under 2 CFR Part 200 and 45 CFR 75.
Given the absence of recent award data and current opportunities in the source, prospective applicants should verify program activity through active NIH grant databases and the NIH SBIR/STTR program announcements before committing development resources. The program's focus on early-stage commercialization of translational technologies positions it as relevant for small businesses with diagnostic, drug, device, or intervention innovations seeking federal validation and commercialization support, but current funding availability and competition cannot be assessed from this source material alone.
Objective and description
- Objective
The National Center for Advancing Translational Sciences' (NCATS') mission is to turn research observations into health solutions through translational science. We work to develop or enhance the development, testing, and implementation of diagnostics
- Description
The National Center for Advancing Translational Sciences (NCATS) Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs help small businesses develop and commercialize new translational technologies.
Eligibility
- Uses of assistance
NCATS is all about getting more treatments to all patients more quickly. A novel drug, device or intervention can take 14 years and $2 billion to develop, with a failure rate exceeding 95%. NCATS is directly addressing this problem by discovering new technologies and other approaches that could greatly accelerate the process of developing and deploying solutions that can be used by all translational researchers. Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs utilize the grant and cooperative agreement mechanisms to help eligible US based small businesses develop new translational technologies that can eventually be commercialized to provide health solutions.
How to apply
- Criteria for selecting proposals
The major elements in evaluating proposals include assessments of: (1) The scientific merit and general significance of the proposed study and its objectives; (2) the technical adequacy of the experimental design and approach; (3) the competency of the proposed investigator or group to successfully pursue the project; (4) the adequacy of the available and proposed facilities and resources; (5) the necessity of the budget components requested in relation to the proposed project; and (6) the relevance and importance to announced program objectives and (7) the availability of funds.
- Award procedure
The initial review of applications from eligible institutions is conducted by committees comprised of authorities in various fields of biomedical research and science education, as appropriate. Each application is given a peer evaluation for merit. Recommendations for award are forwarded to the NCATS Advisory Council for the second level of review and recommendation for award.
- Appeals
From 15 to 30 days. Principal investigators (P.I.) may question the substantive or procedural aspects of the review of their applications by communicating with the NCATS staff. A description of the NIH Peer Review Appeal procedures is available on the NIH home page http://grants.nih.gov/grants/guide/notice-files/NOT-OD-11-064.html
Quick answers
What is Assistance Listing 93.TR5?
Assistance Listing 93.TR5 is National Center for Advancing Translational Sciences - Small Business, a federal grant program run by National Institutes of Health (Department of Health and Human Services).
What is the CFDA number for National Center for Advancing Translational Sciences - Small Business?
Its CFDA number is 93.TR5: Assistance Listing numbers were called CFDA numbers before 2018.
On GovTribe
See this program's full record
- Every grant award and opportunity under it
- Funding by recipient, agency and assistance type
- Alerts for new opportunities
- Ask GovTribe AI about this program